Hims vs Novi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

49 providers verified independently·Independent research·How we rank →

Hims beats Novi overall, scoring 7.9/10 vs 7.8/10. Novi is more affordable at $133/mo vs $199/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-appr. Choose Novi for cash-pay patients who want compounded semaglutide or tirzepa.

A side-by-side comparison of Hims and Novi covering pricing, scores, medication types, insurance, and more to help you decide.

Higher Rated

Hims

#12 of 49

7.9/10

The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership — alongside their existing compounded semaglutide program. Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026) — significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28% — the highest 1-star rate in our table — clustered around subscription/billing complaints.

Visit Hims

Novi

#14 of 49

7.8/10

Telehealth platform for compounded semaglutide and tirzepatide with month-to-month billing, six named clinicians on staff, and a 3-minute pre-approval quiz. Novi emphasizes 'all-in transparent' pricing — medication, supplies, unlimited clinician check-ins, dose adjustments, and weight-loss coaching are bundled with no add-on fees. Standard pricing is $174/mo semaglutide and $283/mo tirzepatide; promotional pricing on the offer landing drops to $99-$133/mo semaglutide and $149-$166/mo tirzepatide with $200 off advertised.

Visit Novi

Feature	Hims	Novi
Our Score	7.9/10	7.8/10
Starting Price	$199/mo	$133/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership — but should know going in that Hims' customer-experience signal is weaker than smaller competitors	Cash-pay patients who want compounded semaglutide or tirzepatide on a no-commitment plan with named clinicians, unlimited check-ins, and aggressive promotional pricing as low as $99-$133/mo on the introductory offer
Ranking	#12	#14

Pros & Cons Compared

Hims

Pros

+Publicly traded company (NYSE: HIMS) — SEC-filed financials, regulatory accountability that private competitors don't have.
+2026 Novo Nordisk partnership — FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
+$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
+Polished app and web experience — among the best user interfaces in men's telehealth.
+8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461) — significant real-world adoption.

Cons

−Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026) — significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
−28% of Trustpilot reviews are 1-star — the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
−Hims reviews span ALL their products (ED, hair loss, mental health, weight loss) — not just GLP-1. But the rating still applies because most users don't separate experiences by product.
−'Hims Oral Kit' is NOT a GLP-1 — it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
−Brand Wegovy at $599/mo is not competitive with LillyDirect/NovoCare cash prices or with Hers ($149/mo for the same product via the same Novo partnership).
−Generic high-volume support — large patient base means less personalized attention than smaller competitors.

Novi

Pros

+Six disclosed clinicians on staff — Daniel Funsch MD, Michael Wasef MD, Takashi Nakamura MD plus three nurse practitioners (Hastings NP, Clements NP, Vergara DNP) — more named providers than most compounded-only platforms publish
+Month-to-month billing with no minimum commitment — cancel before any renewal date with no early-termination penalty
+Aggressive promotional pricing on the offer landing — $99-$133/mo compounded semaglutide and $149-$166/mo compounded tirzepatide with a $200 OFF intro discount
+Unlimited clinician check-ins, dose adjustments, and weight-loss coaching included at no additional cost
+Free 2-day shipping; same active ingredients as Wegovy/Ozempic and Mounjaro/Zepbound (semaglutide and tirzepatide respectively)
+100,000+ patients claimed and editorial coverage in Bloomberg, Forbes, and WebMD provide third-party signal

Cons

−Compounded-only — no FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro through the platform; no Foundayo or oral GLP-1 formats
−Founding year, headquarters city, and corporate ownership are not publicly disclosed
−Promotional $99-$133 pricing applies to the introductory offer landing only — standard rate after any qualifying intro period is $174-$283/mo (verify the renewal rate before enrolling)
−Once medication is dispensed/shipped, prescriptions cannot be returned or refunded — typical for compounded telehealth but worth understanding
−Lab requirements before prescribing are not disclosed on public pages — unclear whether baseline bloodwork is required
−Multiple landing pages (offer-v4, offer-v6-low) show different headline prices, which can create pricing confusion before checkout

Our Verdict

Hims edges out Novi with a score of 7.9/10 vs 7.8/10. If budget is your priority, Novi starts at $133/mo compared to Hims's $199/mo. Hims offers both brand-name and compounded medications, giving you more flexibility. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership — but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose Novi if you want: cash-pay patients who want compounded semaglutide or tirzepatide on a no-commitment plan with named clinicians, unlimited check-ins, and aggressive promotional pricing as low as $99-$133/mo on the introductory offer.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hims nor Novi feels like the right fit, our overall #1 pick across all 49 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review